Acrospire Investment Management LLC increased its position in shares of PRA Health Sciences Inc. (NASDAQ:PRAH) by 8.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,500 shares of the company’s stock after buying an additional 200 shares during the period. Acrospire Investment Management LLC’s holdings in PRA Health Sciences were worth $104,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in PRAH. Acadian Asset Management LLC increased its stake in shares of PRA Health Sciences by 93.3% in the second quarter. Acadian Asset Management LLC now owns 2,330,543 shares of the company’s stock worth $97,324,000 after buying an additional 1,125,077 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in PRA Health Sciences by 22.7% in the first quarter. TimesSquare Capital Management LLC now owns 1,454,855 shares of the company’s stock worth $62,210,000 after buying an additional 269,605 shares during the period. BlackRock Fund Advisors increased its stake in PRA Health Sciences by 6.1% in the first quarter. BlackRock Fund Advisors now owns 1,264,793 shares of the company’s stock worth $54,083,000 after buying an additional 72,562 shares during the period. Emerald Acquisition Ltd. acquired a new stake in PRA Health Sciences during the second quarter worth $23,257,000. Finally, BlackRock Institutional Trust Company N.A. increased its stake in PRA Health Sciences by 0.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 499,489 shares of the company’s stock worth $21,358,000 after buying an additional 3,647 shares during the period.

PRA Health Sciences Inc. (NASDAQ:PRAH) traded up 0.46% during midday trading on Wednesday, reaching $55.00. 309,430 shares of the company’s stock traded hands. The firm’s 50-day moving average is $50.80 and its 200-day moving average is $46.31. PRA Health Sciences Inc. has a 1-year low of $33.00 and a 1-year high of $55.23. The company has a market capitalization of $3.35 billion, a price-to-earnings ratio of 47.17 and a beta of 0.54.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. PRA Health Sciences had a net margin of 4.53% and a return on equity of 20.47%. The business earned $394.20 million during the quarter, compared to analysts’ expectations of $381.25 million. During the same period last year, the business earned $0.47 earnings per share. The business’s revenue for the quarter was up 16.0% on a year-over-year basis. Analysts forecast that PRA Health Sciences Inc. will post $2.47 earnings per share for the current year.

PRAH has been the topic of a number of research reports. Jefferies Group restated a “buy” rating and issued a $57.00 target price on shares of PRA Health Sciences in a report on Friday, July 29th. First Analysis initiated coverage on shares of PRA Health Sciences in a report on Monday, June 20th. They issued an “equal weight” rating and a $47.00 target price on the stock. Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, June 29th. Credit Suisse Group AG initiated coverage on shares of PRA Health Sciences in a report on Monday, June 20th. They issued a “neutral” rating and a $43.00 target price on the stock. Finally, KeyCorp upgraded shares of PRA Health Sciences from a “sector weight” rating to an “overweight” rating and set a $55.00 target price on the stock in a report on Monday, June 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $48.94.

In other PRA Health Sciences news, CEO Colin Shannon sold 113,133 shares of PRA Health Sciences stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $51.57, for a total transaction of $5,834,268.81. Following the completion of the sale, the chief executive officer now directly owns 120,000 shares in the company, valued at $6,188,400. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP David W. Dockhorn sold 107,257 shares of PRA Health Sciences stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $49.00, for a total transaction of $5,255,593.00. The disclosure for this sale can be found here. Company insiders own 2.50% of the company’s stock.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc. (NASDAQ:PRAH).

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.